2010
DOI: 10.1016/j.vaccine.2010.05.065
|View full text |Cite
|
Sign up to set email alerts
|

Control of EHV-1 viremia and nasal shedding by commercial vaccines

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

5
121
1
3

Year Published

2012
2012
2024
2024

Publication Types

Select...
5
2
1

Relationship

0
8

Authors

Journals

citations
Cited by 82 publications
(130 citation statements)
references
References 28 publications
5
121
1
3
Order By: Relevance
“…According to Soboll-Hussey et al (35), horses experimentally infected with a neuropathogenic EHV-1 strain produced almost no IgG3/5, short-lived IgG1 and IgG6, and strong IgG4/7 responses that mimicked the increase in SN titers. Goehring et al (12) similarly observed correlations of IgG1 and IgG4/7 with SN patterns following a high-dose experimental infection with a neuropathogenic strain of EHV-1, providing further evidence of the diagnostic value of these markers as correlates of protection. Field-based evidence from natural infections, however, is still lacking.…”
mentioning
confidence: 84%
See 2 more Smart Citations
“…According to Soboll-Hussey et al (35), horses experimentally infected with a neuropathogenic EHV-1 strain produced almost no IgG3/5, short-lived IgG1 and IgG6, and strong IgG4/7 responses that mimicked the increase in SN titers. Goehring et al (12) similarly observed correlations of IgG1 and IgG4/7 with SN patterns following a high-dose experimental infection with a neuropathogenic strain of EHV-1, providing further evidence of the diagnostic value of these markers as correlates of protection. Field-based evidence from natural infections, however, is still lacking.…”
mentioning
confidence: 84%
“…The available inactivated vaccines are mostly effective at generating serum virus neutralization (SN) responses, possibly due to the feasibility of SN testing in the vaccine screening process. In addition, one modified-live virus (MLV) vaccine is available in North America, and it confers a high level of protection against fever and other clinical signs of disease but is not labeled for use in pregnant mares (12,13). No vaccine is completely effective at eliminating nasopharyngeal virus shedding or cell-associated viremia, which are the detectable parameters of most concern.…”
mentioning
confidence: 99%
See 1 more Smart Citation
“…However, unlike EIV there are no definitive immune correlates of protection to assess vaccine efficacy against EHV‐1/4. Nevertheless, in several vaccination studies serum‐neutralising (SN) antibodies have correlated with protection against some clinical signs and reduced duration of virus shedding 9, 10, 11. The objective of this study was to evaluate virus‐specific antibody titres induced following concurrent and consecutive vaccination against EIV and EHV‐1/4 using the inactivated whole‐virus EIV vaccine Duvaxyn IE Plus and the inactivated bivalent EHV‐1/4 vaccine Duvaxyn EHV‐1,4.…”
Section: Introductionmentioning
confidence: 99%
“…Anti-IgGa CVS48 recognizes recombinant equine IgG1 exclusively, anti-IgGb CVS39 recognizes recombinant IgG4 and IgG7, while anti-IgG(T) CVS38 strongly recognizes recombinant IgG5 but also displays some weak recognition of recombinant IgG3 (6). In addition, MAbs 159-4 and 416-2 were used to identify IgG3 and IgG5, respectively (2,23). Sera (or plasma) were diluted 1:500 for all merozoitespecific IgG subclass ELISAs.…”
mentioning
confidence: 99%